ATE432993T1 - Tar rna bindende peptide - Google Patents

Tar rna bindende peptide

Info

Publication number
ATE432993T1
ATE432993T1 AT00968684T AT00968684T ATE432993T1 AT E432993 T1 ATE432993 T1 AT E432993T1 AT 00968684 T AT00968684 T AT 00968684T AT 00968684 T AT00968684 T AT 00968684T AT E432993 T1 ATE432993 T1 AT E432993T1
Authority
AT
Austria
Prior art keywords
methods
screening
rna
compounds
dye
Prior art date
Application number
AT00968684T
Other languages
English (en)
Inventor
Tariq Rana
Original Assignee
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Jersey Med filed Critical Univ New Jersey Med
Application granted granted Critical
Publication of ATE432993T1 publication Critical patent/ATE432993T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
AT00968684T 1999-10-04 2000-10-04 Tar rna bindende peptide ATE432993T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15764699P 1999-10-04 1999-10-04
PCT/US2000/027389 WO2001025486A1 (en) 1999-10-04 2000-10-04 Methods for identifying rna binding compounds

Publications (1)

Publication Number Publication Date
ATE432993T1 true ATE432993T1 (de) 2009-06-15

Family

ID=22564644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968684T ATE432993T1 (de) 1999-10-04 2000-10-04 Tar rna bindende peptide

Country Status (8)

Country Link
US (5) US6503713B1 (de)
EP (3) EP1226115A4 (de)
JP (2) JP2003511362A (de)
AT (1) ATE432993T1 (de)
AU (2) AU7855900A (de)
CA (2) CA2386540A1 (de)
DE (1) DE60042338D1 (de)
WO (2) WO2001025188A1 (de)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
AU2002211475A1 (en) * 2000-10-04 2002-04-15 University Of Medicine And Dentistry Of New Jersey Site-specific protein modification
US20050142545A1 (en) * 2001-04-11 2005-06-30 Conn Michael M. Methods for identifying small molecules that bind specific rna structural motifs
US20060228730A1 (en) * 2001-04-11 2006-10-12 Rando Robert F Methods for identifying small molecules that bind specific RNA structural motifs
US6649573B2 (en) * 2001-04-13 2003-11-18 Michael J. Mitrovich Solid lubricant and composition
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract
JP2005514603A (ja) * 2001-11-06 2005-05-19 アジリックス・コーポレイション 高感度コード化検出システム
US20030229082A1 (en) * 2002-01-16 2003-12-11 The Regents Of The University Of California Inhibition of RNA function
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
AU2003252136A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US20040018495A1 (en) * 2002-07-24 2004-01-29 Xing-Xiang Li Microparticle based signal amplification for the detection of analytes
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP2006521116A (ja) * 2003-03-27 2006-09-21 ピーティーシー セラピューティクス，インコーポレーテッド 抗真菌性および／または抗増殖性分子を同定するためのｔＲＮＡスプライシング経路の酵素の標的化
WO2004087069A2 (en) * 2003-03-27 2004-10-14 Ptc Therapeutics, Inc. METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS
CA2520510A1 (en) * 2003-03-27 2004-10-14 Ptc Therapeutics, Inc. Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-fungal agents
EP3167935B1 (de) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Verfahren und trägerkomplexe zur abgabe von molekülen an zellen
AU2004236740A1 (en) * 2003-05-02 2004-11-18 Sigma-Aldrich Co. Solid phase cell lysis and capture platform
EP1649002A4 (de) 2003-07-02 2009-06-03 Ptc Therapeutics Inc Rna prozessierende proteinkomplexe und verwendungen davon
US20050064470A1 (en) * 2003-07-17 2005-03-24 Rana Tariq M. High throughput screening methods for identifying RNA binding compounds
DE602004021829D1 (de) * 2003-09-11 2009-08-13 Idexx Lab Inc Verfahren zum nachweis des felinen immunschwächevirus
AU2005267607B8 (en) * 2003-09-11 2009-07-16 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2004304348B2 (en) * 2003-12-18 2009-02-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
WO2005077125A2 (en) * 2004-02-11 2005-08-25 Applera Corporation Methods and compositions for detecting nucleic acids
US20060069050A1 (en) * 2004-02-17 2006-03-30 University Of Massachusetts Methods and compositions for mediating gene silencing
ATE504834T1 (de) * 2004-02-19 2011-04-15 Idexx Lab Inc Verfahren und vorrichtung zum nachweis von katzen-immunschwächevirus
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
JP4662988B2 (ja) * 2004-06-30 2011-03-30 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスを検出するための方法および装置
CA2576930C (en) * 2004-06-30 2011-06-07 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein
WO2006026248A1 (en) * 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
KR100780405B1 (ko) 2005-08-31 2007-11-28 재단법인서울대학교산학협력재단 알파 나선형 펩티드를 이용한 ｒｎａ 특이적 결합 펩티드탐색 방법
WO2007030521A1 (en) * 2005-09-06 2007-03-15 Invitrogen Corporation Control of chemical modification
EP3725324A1 (de) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatisch-kationisches peptid zur verwendung in einem verfahren zur reduzierung der cd36-expression
US20100184643A1 (en) * 2006-08-22 2010-07-22 University Of Virginia Patent Foundation Methods and Compounds Regulating the Erythroid Response to Iron Deficiency
WO2008024499A2 (en) * 2006-08-25 2008-02-28 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
WO2008064304A2 (en) * 2006-11-22 2008-05-29 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
JP2010519337A (ja) * 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
CN104383556B (zh) 2007-05-16 2018-06-05 布里格姆妇女医院 突触核蛋白病的治疗
US8901487B2 (en) 2007-07-20 2014-12-02 George Washington University Subcellular analysis by laser ablation electrospray ionization mass spectrometry
US7964843B2 (en) 2008-07-18 2011-06-21 The George Washington University Three-dimensional molecular imaging by infrared laser ablation electrospray ionization mass spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
ATE553764T1 (de) * 2007-09-14 2012-05-15 Trana Discovery Zusammensetzungen und verfahren zur identifizierung von inhibitoren einer retrovirusinfektion
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
US8530182B2 (en) * 2007-12-05 2013-09-10 Centers For Disease Control And Prevention Viral protein quantification process and vaccine quality control therewith
US8673884B2 (en) * 2008-02-05 2014-03-18 Versitech Limited Anti-influenza compounds
EP2712620A1 (de) 2008-02-07 2014-04-02 Cornell University Verfahren zur Vorbeugung oder Behandlung von Insulinresistenz
CN107802821A (zh) 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
CA2776044A1 (en) * 2008-09-29 2010-04-01 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
SI2607484T1 (sl) 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
SG173627A1 (en) 2009-02-13 2011-09-29 Chem Inc X Methods of creating and screening dna-encoded libraries
EP3563862B1 (de) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosin-lys-phe-nh2 zur verhinderung von sekundären komplikationen von brandverletzungen
US9399032B2 (en) 2009-05-14 2016-07-26 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
SI3708178T1 (sl) 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
EP3603658B1 (de) 2009-10-05 2025-01-08 Cornell University Peptide zur verwendung in der behandlung von herzinsuffizienz verursacht durch hypertrophe cardiomyopathy
WO2011123781A1 (en) 2010-04-02 2011-10-06 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
ES2562821T3 (es) 2010-10-21 2016-03-08 Advanced Cell Diagnostics, Inc. Método ultrasensible para la detección in situ de ácidos nucleicos
US20130288364A1 (en) * 2010-10-28 2013-10-31 Whitehead Institute For Biomedical Research Engineered kinetochores and uses thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
US8829426B2 (en) 2011-07-14 2014-09-09 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
ES2646716T3 (es) 2011-09-05 2017-12-15 Stichting Katholieke Universiteit Oligonucleótidos antisentido para el tratamiento de amaurosis congénita de Leber
DK2748357T3 (en) 2011-09-07 2018-07-16 X Chem Inc Methods for labeling DNA-encoded libraries
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP2836514A4 (de) 2012-04-13 2015-12-30 Childrens Medical Center Tiki-inhibitoren
KR102146721B1 (ko) 2012-07-13 2020-08-21 엑스-켐, 인크. 폴리머라제에 의해 판독가능하지 않은 코딩 올리고뉴클레오티드 연결을 갖는 dna-코딩된 라이브러리
US9738623B2 (en) 2012-08-06 2017-08-22 The General Hospital Corporation Curcumin analogs
EP3901280B1 (de) 2012-10-17 2025-03-12 10x Genomics Sweden AB Verfahren und produkt zur optimierung einer lokalisierten oder räumlichen detektion einer genexpression in einer gewebeprobe
CA2904350A1 (en) 2013-03-15 2014-09-25 The General Hospital Corporation Glycine, mitochondrial one-carbon metabolism, and cancer
CA2912389C (en) 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
CN111500680B (zh) 2013-06-25 2024-04-16 普罗格诺西斯生物科学公司 检测样品中生物靶标的空间分布的方法和系统
US9757477B2 (en) 2013-09-06 2017-09-12 The General Hospital Corporation Imaging brown adipose tissue with curcumin derivatives
WO2015187938A1 (en) 2014-06-05 2015-12-10 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of invasive aspergillosis
US10131910B2 (en) 2014-07-10 2018-11-20 Stichting Katholieke Universiteit Antisense oligonucleotides for the treatment of Usher syndrome type 2
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
EP4321627A3 (de) 2015-04-10 2024-04-17 10x Genomics Sweden AB Räumlich getrennte multiplex-nukleinsäureanalyse von biologischen proben
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
CN108139375A (zh) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
MX2018013003A (es) 2016-04-25 2019-01-28 Proqr Therapeutics Ii Bv Oligonucleotidos para tratar una enfermedad ocular.
WO2017197386A1 (en) 2016-05-13 2017-11-16 The Brigham And Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi
US10981980B2 (en) 2016-06-15 2021-04-20 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
EP3479102A1 (de) * 2016-07-04 2019-05-08 CellTool GmbH Vorrichtung und verfahren zur bestimmung von transfektionen
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
US11994510B2 (en) 2016-10-11 2024-05-28 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of Fusariosis and Scedosporiosis
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US20230152257A1 (en) * 2017-09-25 2023-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing
EP3700527A4 (de) 2017-10-25 2021-03-10 Children's Medical Center Corporation Papd5-inhibitoren und verfahren zur verwendung davon
MA52635A (fr) 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
EP3894585A2 (de) 2018-12-10 2021-10-20 10X Genomics, Inc. Erzeugung von erfassungssonden zur räumlichen analyse
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
ES2974189T3 (es) 2019-02-07 2024-06-26 Massachusetts Gen Hospital Carotenoides C50 para tratar o prevenir las náuseas
CN113597471B (zh) * 2019-04-16 2025-07-25 弗·哈夫曼-拉罗切有限公司 使用修饰珠的小分子筛选细胞分析
EP3959197A4 (de) 2019-04-24 2022-10-12 Children's Medical Center Corporation Papd5-inhibitoren und verfahren zur verwendung davon
AU2020282792B2 (en) 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
EP3976820A1 (de) 2019-05-30 2022-04-06 10X Genomics, Inc. Verfahren zum nachweis der räumlichen heterogenität einer biologischen probe
WO2021091611A1 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
EP4025711A2 (de) 2019-11-08 2022-07-13 10X Genomics, Inc. Erhöhung der spezifität einer analytbindung
CN121022991A (zh) 2019-12-23 2025-11-28 10X基因组学有限公司 使用rna模板化连接进行空间分析的方法
EP4081656A1 (de) 2019-12-23 2022-11-02 10X Genomics, Inc. Zusammensetzungen und verfahren zur verwendung von fixierten biologischen proben bei partitionsbasierten tests
EP4752521A3 (de) 2019-12-23 2026-08-12 10X Genomics, Inc. Reversible fixierreagenzien und verfahren zur verwendung davon
US12365942B2 (en) 2020-01-13 2025-07-22 10X Genomics, Inc. Methods of decreasing background on a spatial array
US12405264B2 (en) 2020-01-17 2025-09-02 10X Genomics, Inc. Electrophoretic system and method for analyte capture
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US20210230681A1 (en) 2020-01-24 2021-07-29 10X Genomics, Inc. Methods for spatial analysis using proximity ligation
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US12076701B2 (en) 2020-01-31 2024-09-03 10X Genomics, Inc. Capturing oligonucleotides in spatial transcriptomics
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US12129516B2 (en) 2020-02-07 2024-10-29 10X Genomics, Inc. Quantitative and automated permeabilization performance evaluation for spatial transcriptomics
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US12281357B1 (en) 2020-02-14 2025-04-22 10X Genomics, Inc. In situ spatial barcoding
US12399123B1 (en) 2020-02-14 2025-08-26 10X Genomics, Inc. Spatial targeting of analytes
CN116157533A (zh) 2020-02-21 2023-05-23 10X基因组学有限公司 使用杂交方法捕获遗传靶标
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
EP4139485B1 (de) 2020-04-22 2023-09-06 10X Genomics, Inc. Verfahren zur räumlichen analyse unter verwendung von gezieltem rna-abbau
US12416603B2 (en) 2020-05-19 2025-09-16 10X Genomics, Inc. Electrophoresis cassettes and instrumentation
AU2021275906A1 (en) 2020-05-22 2022-12-22 10X Genomics, Inc. Spatial analysis to detect sequence variants
EP4153775B1 (de) 2020-05-22 2024-07-24 10X Genomics, Inc. Simultane räumlich-zeitliche messung der genexpression und der zellaktivität
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
EP4025692A2 (de) 2020-06-02 2022-07-13 10X Genomics, Inc. Nukleinsäure-bibliotheksverfahren
US12265079B1 (en) 2020-06-02 2025-04-01 10X Genomics, Inc. Systems and methods for detecting analytes from captured single biological particles
EP4600376A3 (de) 2020-06-02 2025-10-22 10X Genomics, Inc. Räumliche transkriptomik für antigenrezeptoren
US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
EP4421186B1 (de) 2020-06-08 2025-08-13 10X Genomics, Inc. Verfahren zur bestimmung eines chirurgischen randes und verfahren zur verwendung davon
EP4446430A3 (de) 2020-06-10 2024-12-18 10X Genomics, Inc. Verfahren zur bestimmung einer position eines analyten in einer biologischen probe
US12435363B1 (en) 2020-06-10 2025-10-07 10X Genomics, Inc. Materials and methods for spatial transcriptomics
EP4164796A4 (de) 2020-06-10 2024-03-06 10x Genomics, Inc. Flüssigkeitsabgabeverfahren
EP4450639B1 (de) 2020-06-25 2025-10-15 10X Genomics, Inc. Räumliche analyse der dna-methylierung
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US12209280B1 (en) 2020-07-06 2025-01-28 10X Genomics, Inc. Methods of identifying abundance and location of an analyte in a biological sample using second strand synthesis
US12553898B1 (en) 2020-08-10 2026-02-17 10X Genomics, Inc. Fluorescent hybridization of antibody-oligonucleotide for multiplexing and signal amplification
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
CN116194590A (zh) 2020-09-18 2023-05-30 10X基因组学有限公司 样品处理设备和图像配准方法
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
WO2022140028A1 (en) 2020-12-21 2022-06-30 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
ES2989523T3 (es) 2021-02-19 2024-11-26 10X Genomics Inc Método de uso de un dispositivo modular de soporte para ensayos
EP4524261B1 (de) 2021-03-18 2026-07-22 10X Genomics, Inc. Multiplex-erfassung von gen- und proteinexpression aus einer biologischen probe
EP4305196B1 (de) 2021-04-14 2025-04-02 10X Genomics, Inc. Verfahren zur messung der fehllokalisierung eines analyten
EP4320271B1 (de) 2021-05-06 2025-03-19 10X Genomics, Inc. Verfahren zur erhöhung der auflösung von räumlicher analyse
ES3030033T3 (en) 2021-06-03 2025-06-26 10X Genomics Inc Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
US12553805B2 (en) 2021-08-02 2026-02-17 10X Genomics, Inc. Methods of preserving a biological sample
WO2023034489A1 (en) 2021-09-01 2023-03-09 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
EP4419707A1 (de) 2021-11-10 2024-08-28 10X Genomics, Inc. Verfahren, zusammensetzungen und kits zur bestimmung der position eines analyten in einer biologischen probe
EP4305195A2 (de) 2021-12-01 2024-01-17 10X Genomics, Inc. Verfahren, zusammensetzungen und systeme für verbesserten in-situ-nachweis von analyten und raumanalyse
EP4441711A1 (de) 2021-12-20 2024-10-09 10X Genomics, Inc. Selbsttest für eine pathologie-/histologie-objektträgerbildgebungsvorrichtung
US20250282714A1 (en) * 2022-03-23 2025-09-11 Duke University Compositions for and methods of modulating rna stability
US12637706B2 (en) 2022-03-23 2026-05-26 10X Genomics, Inc. Methods and compositions related to microsphere surface gelation
DE102022124232A1 (de) 2022-09-21 2024-03-21 Carl von Ossietzky Universität Oldenburg, Körperschaft des öffentlichen Rechts Antisense-Oligonukleotide für die Behandlung des Joubert-Syndroms
EP4685239A1 (de) 2022-11-09 2026-01-28 10X Genomics, Inc. Verfahren, zusammensetzungen und kits zur bestimmung der position mehrerer analyten in einer biologischen probe

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
ATE88761T1 (de) 1986-01-10 1993-05-15 Amoco Corp Kompetitiver homogener test.
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JPH06511387A (ja) * 1991-12-24 1994-12-22 アイシス・ファーマシューティカルス・インコーポレーテッド β−アミロイド調節のための組成物および方法
US5721099A (en) * 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
CA2163637C (en) 1993-05-27 2008-05-06 Michal Lebl Topologically segregated, encoded solid phase libraries
WO1995005389A1 (en) * 1993-08-18 1995-02-23 The Board Of Trustees Of The Leland Stanford Junior University Sequence-specific glycoconjugate transcriptional antagonists
JPH09511486A (ja) * 1994-01-13 1997-11-18 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 合成レセプター、ライブラリー及びこれらの使用
US5712096A (en) * 1994-08-23 1998-01-27 University Of Massachusetts Medical Center Oligoribonucleotide assays for novel antibiotics
US5627210A (en) * 1995-02-06 1997-05-06 Chiron Corporation Branched combinatorial libraries
US5593835A (en) * 1995-05-12 1997-01-14 President And Fellows Of Harvard College Methods and kits for RNA binding compounds
CA2203832A1 (en) * 1995-09-08 1997-03-13 Jaime E. Arenas Screen for compounds with affinity for rna
US5666341A (en) * 1995-09-18 1997-09-09 Matsushita Electric Industrial Co., Ltd. Data detection apparatus
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US6107029A (en) 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US6004749A (en) 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
US5843995A (en) * 1997-07-07 1998-12-01 University Of Medicine And Dentistry Of New Jersey Inhibition of HIV-1 replication using oligocarbamate derivatives
AU744755B2 (en) * 1997-11-12 2002-03-07 Brigham And Women's Hospital The translation enhancer element of the human amyloid precursor protein gene

Also Published As

Publication number Publication date
EP1218544A4 (de) 2005-05-25
US6420591B1 (en) 2002-07-16
JP2003511045A (ja) 2003-03-25
DE60042338D1 (de) 2009-07-16
JP2003511362A (ja) 2003-03-25
US6503713B1 (en) 2003-01-07
EP1218544B1 (de) 2009-06-03
WO2001025486A1 (en) 2001-04-12
US20030153523A1 (en) 2003-08-14
AU7855900A (en) 2001-05-10
AU7856600A (en) 2001-05-10
EP1226115A1 (de) 2002-07-31
EP2071036A3 (de) 2009-09-09
EP1218544A1 (de) 2002-07-03
CA2386239A1 (en) 2001-04-12
EP1226115A4 (de) 2006-03-15
US20050221368A1 (en) 2005-10-06
US6583309B1 (en) 2003-06-24
CA2386540A1 (en) 2001-04-12
WO2001025188A1 (en) 2001-04-12
US6875736B2 (en) 2005-04-05
EP2071036A2 (de) 2009-06-17

Similar Documents

Publication Publication Date Title
DE60042338D1 (de) TAR RNA bindende Peptide
TW200506066A (en) Modulation of protein functionalities
ATE470150T1 (de) Methode zum schnellen identifizieren von kleinen organischen liganden
JP2002507748A5 (de)
ATE488586T1 (de) In vitro peptid-expressionsbank
CA2395724A1 (en) Nucleic acids, proteins, and antibodies
ES2117050T3 (es) Ensayo de cribado para la deteccion de moleculas de union al adn.
WO2005023986A3 (en) Microrna as ligands and target molecules
DK1512015T3 (da) Fremgangsmåder til forbedring af bindingsegenskaber hos et molekyle
EP1147123A4 (de) Neuartige geruchsrezeptoren in drosophila
Miao et al. Inhibition of high-mobility-group A2 protein binding to DNA by netropsin: a biosensor-surface plasmon resonance assay
WO2004042083A3 (en) Nucleic acid ligands and uses therefor
Fan et al. Rapid fluorescence immunoassay of benzo [a] pyrene in mainstream cigarette smoke based on a dual-functional antibody–DNA conjugate
WO2015166491A2 (en) Fluorescent molecular sensor for targeting changes in protein surfaces, and methods of use thereof
DE69939275D1 (de) Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon
DE69924147D1 (de) Floureszenzintensitäts-test für eine protein- oder peptidbindung an nukleinsäuren
Silva et al. Protein purification by aminosquarylium cyanine dye‐affinity chromatography
Kriegelsteinová et al. Copper‐free solid‐phase synthesis of triazolo [1, 5‐a][1, 4] diazepin‐6‐ones
EA200701578A1 (ru) Способ конъюгирования молекул, содержащих аминотиол, к носителям
WO2003077872A3 (en) Cell surface tropomyosin as a target of angiogenesis inhibition
Arnusch et al. Solid phase synthesis of vancomycin mimics
Katritzky et al. N‐Fmoc‐protected (α‐dipeptidoyl) benzotriazoles for efficient solid‐phase peptide synthesis by segment condensation
Nishio et al. Structural differences between myofibrillar protein, paratropomyosin, and tropomyosin as revealed by high‐performance liquid chromatography
Nakamura et al. Tailored synthesis of 162‐residue S‐monoglycosylated GM2‐activator protein (GM2AP) analogues that allows facile access to a protein library
Giron et al. Cysteine‐reactive covalent capture tags for enrichment of cysteine‐containing peptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties